Literature DB >> 23889343

Mycobacterium tuberculosis shikimate kinase inhibitors: design and simulation studies of the catalytic turnover.

Beatriz Blanco1, Verónica Prado, Emilio Lence, José M Otero, Carmela Garcia-Doval, Mark J van Raaij, Antonio L Llamas-Saiz, Heather Lamb, Alastair R Hawkins, Concepción González-Bello.   

Abstract

Shikimate kinase (SK) is an essential enzyme in several pathogenic bacteria and does not have any counterpart in human cells, thus making it an attractive target for the development of new antibiotics. The key interactions of the substrate and product binding and the enzyme movements that are essential for catalytic turnover of the Mycobacterium tuberculosis shikimate kinase enzyme (Mt-SK) have been investigated by structural and computational studies. Based on these studies several substrate analogs were designed and assayed. The crystal structure of Mt-SK in complex with ADP and one of the most potent inhibitors has been solved at 2.15 Å. These studies reveal that the fixation of the diaxial conformation of the C4 and C5 hydroxyl groups recognized by the enzyme or the replacement of the C3 hydroxyl group in the natural substrate by an amino group is a promising strategy for inhibition because it causes a dramatic reduction of the flexibility of the LID and shikimic acid binding domains. Molecular dynamics simulation studies showed that the product is expelled from the active site by three arginines (Arg117, Arg136, and Arg58). This finding represents a previously unknown key role of these conserved residues. These studies highlight the key role of the shikimic acid binding domain in the catalysis and provide guidance for future inhibitor designs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23889343     DOI: 10.1021/ja405853p

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  13 in total

1.  Biochemical, Kinetic, and Computational Structural Characterization of Shikimate Kinase from Methicillin-Resistant Staphylococcus aureus.

Authors:  Alejandro Favela-Candia; Alfredo Téllez-Valencia; Mara Campos-Almazán; Erick Sierra-Campos; Mónica Valdez-Solana; Jesús Oria-Hernández; Adriana Castillo-Villanueva; Hugo Nájera; Claudia Avitia-Domínguez
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

2.  Structure of type II dehydroquinase from Pseudomonas aeruginosa.

Authors:  Scott Reiling; Alan Kelleher; Monica M Matsumoto; Gonteria Robinson; Oluwatoyin A Asojo
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-10-25       Impact factor: 1.056

3.  Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.

Authors:  Paulo H de S Miranda; Estela M G Lourenço; Alexander M S Morais; Pedro I C de Oliveira; Priscilla S de S N Silverio; Alessandro K Jordão; Euzébio G Barbosa
Journal:  Mol Divers       Date:  2019-12-09       Impact factor: 2.943

Review 4.  Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials.

Authors:  Sara Gordon; Johayra Simithy; Douglas C Goodwin; Angela I Calderón
Journal:  Perspect Medicin Chem       Date:  2015-03-15

Review 5.  A Multifaceted Role of Tryptophan Metabolism and Indoleamine 2,3-Dioxygenase Activity in Aspergillus fumigatus-Host Interactions.

Authors:  Tsokyi Choera; Teresa Zelante; Luigina Romani; Nancy P Keller
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

Review 6.  A Three-Ring Circus: Metabolism of the Three Proteogenic Aromatic Amino Acids and Their Role in the Health of Plants and Animals.

Authors:  Anutthaman Parthasarathy; Penelope J Cross; Renwick C J Dobson; Lily E Adams; Michael A Savka; André O Hudson
Journal:  Front Mol Biosci       Date:  2018-04-06

7.  Multiple Substrate Usage of Coxiella burnetii to Feed a Bipartite Metabolic Network.

Authors:  Ina Häuslein; Franck Cantet; Sarah Reschke; Fan Chen; Matteo Bonazzi; Wolfgang Eisenreich
Journal:  Front Cell Infect Microbiol       Date:  2017-06-29       Impact factor: 5.293

Review 8.  Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors:  José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal:  Molecules       Date:  2020-03-11       Impact factor: 4.411

9.  Finding the First Potential Inhibitors of Shikimate Kinase from Methicillin Resistant Staphylococcus aureus through Computer-Assisted Drug Design.

Authors:  Lluvia Rios-Soto; Alfredo Téllez-Valencia; Erick Sierra-Campos; Mónica Valdez-Solana; Jorge Cisneros-Martínez; Marcelo Gómez Palacio-Gastélum; Adriana Castillo-Villanueva; Claudia Avitia-Domínguez
Journal:  Molecules       Date:  2021-11-08       Impact factor: 4.411

10.  Virtualizing the p-ANAPL library: a step towards drug discovery from African medicinal plants.

Authors:  Fidele Ntie-Kang; Pascal Amoa Onguéné; Ghislain W Fotso; Kerstin Andrae-Marobela; Merhatibeb Bezabih; Jean Claude Ndom; Bonaventure T Ngadjui; Abiodun O Ogundaini; Berhanu M Abegaz; Luc Mbaze Meva'a
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.